{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:30:52Z","timestamp":1794047452234,"version":"4.8.0"},"reference-count":50,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"5","license":[{"start":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T00:00:00Z","timestamp":1700092800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Multiple myeloma (MM) is a malignancy of plasma cells whose antibody secretion creates proteotoxic stress relieved by the N-end rule pathway, a proteolytic system that degrades N-arginylated proteins in the proteasome. When the proteasome is inhibited, protein cargo is alternatively targeted for autophagic degradation by binding to the ZZ-domain of p62\/ sequestosome-1. Here, we demonstrate that XRK3F2, a selective ligand for the ZZ-domain, dramatically improved two major responses to the proteasome inhibitor bortezomib (Btz) by increasing: i) killing of human MM cells by stimulating both Btz-mediated apoptosis and necroptosis, a process regulated by p62; and ii) preservation of bone mass by stimulating osteoblast differentiation and inhibiting osteoclastic bone destruction. Co-administration of Btz and XRK3F2 inhibited both branches of the bimodal N-end rule pathway exhibited synergistic anti-MM effects on MM cell lines and CD138+ cells from MM patients, and prevented stromal-mediated MM cell survival. In mice with established human MM, co-administration of Btz and XRK3F2 decreased tumor burden and prevented the progression of MM-induced osteolytic disease by inducing new bone formation more effectively than either single agent alone. The results suggest that p62-ZZ ligands enhance the anti- MM efficacy of proteasome inhibitors and can reduce MM morbidity and mortality by improving bone health.<\/jats:p>","DOI":"10.3324\/haematol.2023.283787","type":"journal-article","created":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T02:31:10Z","timestamp":1700101870000},"page":"1501-1513","source":"Crossref","is-referenced-by-count":5,"title":["Pharmacologic targeting of the p62 ZZ domain enhances both anti-tumor and bone-anabolic effects of bortezomib in multiple myeloma"],"prefix":"10.3324","volume":"109","author":[{"given":"Silvia","family":"Marino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela N.","family":"Petrusca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan T.","family":"Bishop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith L.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayley M.","family":"Sabol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cody","family":"Ashby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin H.","family":"Layer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Cesarano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Utpal P.","family":"Dav\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiana","family":"Perna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus","family":"Delgado-Calle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Chirgwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. David","family":"Roodman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2023,11,16]]},"reference":[{"key":"60731","doi-asserted-by":"crossref","unstructured":"Marino S, Petrusca DN, Roodman GD. Therapeutic targets in myeloma bone disease. Br J Pharmacol. 2021; 178(9):1907-1922.","DOI":"10.1111\/bph.14889"},{"key":"60732","doi-asserted-by":"crossref","unstructured":"van de Donk N, Pawlyn C, Yong KL. Multiple myeloma. Lancet. 2021; 397(10272):410-427.","DOI":"10.1016\/S0140-6736(21)00135-5"},{"key":"60733","doi-asserted-by":"crossref","unstructured":"Dima D, Jiang D, Singh DJ. Multiple myeloma therapy: emerging trends and challenges. Cancers (Basel). 2022; 14(17):4082.","DOI":"10.3390\/cancers14174082"},{"key":"60734","doi-asserted-by":"crossref","unstructured":"Garrett IR, Chen D, Gutierrez G. Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro. J Clin Invest. 2003; 111(11):1771-1782.","DOI":"10.1172\/JCI16198"},{"key":"60735","doi-asserted-by":"crossref","unstructured":"Oyajobi BO, Garrett IR, Gupta A. Stimulation of new bone formation by the proteasome inhibitor, bortezomib: implications for myeloma bone disease. Br J Haematol. 2007; 139(3):434-438.","DOI":"10.1111\/j.1365-2141.2007.06829.x"},{"key":"60736","doi-asserted-by":"crossref","unstructured":"Giuliani N, Morandi F, Tagliaferri S. The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients. Blood. 2007; 110(1):334-338.","DOI":"10.1182\/blood-2006-11-059188"},{"key":"60737","doi-asserted-by":"crossref","unstructured":"Mukherjee S, Raje N, Schoonmaker JA. Pharmacologic targeting of a stem\/progenitor population in vivo is associated with enhanced bone regeneration in mice. J Clin Invest. 2008; 118(2):491-504.","DOI":"10.1172\/JCI33102"},{"key":"60738","doi-asserted-by":"crossref","unstructured":"Marino S, Roodman GD. Multiple myeloma and bone: the fatal interaction. Cold Spring Harb Perspect Med. 2018; 8(8):a031286.","DOI":"10.1101\/cshperspect.a031286"},{"key":"60739","doi-asserted-by":"crossref","unstructured":"Tao J, Srinivasan V, Yi X. Bone-targeted bortezomib inhibits bortezomib-resistant multiple myeloma in mice by providing higher levels of bortezomib in bone. J Bone Miner Res. 2022; 37(4):629-642.","DOI":"10.1002\/jbmr.4496"},{"key":"60740","doi-asserted-by":"crossref","unstructured":"van Anken E, Bakunts A, Hu CA, Janssens S, Sitia R. Molecular evaluation of endoplasmic reticulum homeostasis meets humoral immunity. Trends Cell Biol. 2021; 31(7):529-541.","DOI":"10.1016\/j.tcb.2021.02.004"},{"key":"60741","doi-asserted-by":"crossref","unstructured":"Shim SM, Choi HR, Sung KW. The endoplasmic reticulumresiding chaperone BiP is short-lived and metabolized through N-terminal arginylation. Sci Signal. 2018; 11(511):eaan0630.","DOI":"10.1126\/scisignal.aan0630"},{"key":"60742","doi-asserted-by":"crossref","unstructured":"Varshavsky A. The N-end rule pathway and regulation by proteolysis. Protein Sci. 2011; 20(8):1298-1345.","DOI":"10.1002\/pro.666"},{"key":"60743","doi-asserted-by":"crossref","unstructured":"Cha-Molstad H, Sung KS, Hwang J. Amino-terminal arginylation targets endoplasmic reticulum chaperone BiP for autophagy through p62 binding. Nat Cell Biol. 2015; 17(7):917-929.","DOI":"10.1038\/ncb3177"},{"key":"60744","doi-asserted-by":"crossref","unstructured":"Kwon DH, Park OH, Kim L. Insights into degradation mechanism of N-end rule substrates by p62\/SQSTM1 autophagy adapter. Nat Commun. 2018; 9(1):3291.","DOI":"10.1038\/s41467-018-05825-x"},{"key":"60745","doi-asserted-by":"crossref","unstructured":"Yoo YD, Mun SR, Ji CH. N-terminal arginylation generates a bimodal degron that modulates autophagic proteolysis. Proc Natl Acad Sci U S A. 2018; 115(12):E2716-e2724.","DOI":"10.1073\/pnas.1719110115"},{"key":"60746","doi-asserted-by":"crossref","unstructured":"Kumar AV, Mills J, Lapierre LR. Selective autophagy receptor p62\/SQSTM1, a pivotal player in stress and aging. Front Cell Dev Biol. 2022; 10:793328.","DOI":"10.3389\/fcell.2022.793328"},{"key":"60747","doi-asserted-by":"crossref","unstructured":"Teramachi J, Silbermann R, Yang P. Blocking the ZZ domain of sequestosome1\/p62 suppresses myeloma growth and osteoclast formation in vitro and induces dramatic bone formation in myeloma-bearing bones in vivo. Leukemia. 2016; 30(2):390-398.","DOI":"10.1038\/leu.2015.229"},{"key":"60748","doi-asserted-by":"crossref","unstructured":"Adamik J, Silbermann R, Marino S. XRK3F2 inhibition of p62-ZZ domain signaling rescues myeloma-induced GFI1-driven epigenetic repression of the Runx2 gene in pre-osteoblasts to overcome differentiation suppression. Front Endocrinol (Lausanne). 2018; 9:344.","DOI":"10.3389\/fendo.2018.00344"},{"key":"60749","doi-asserted-by":"crossref","unstructured":"Hiruma Y, Honjo T, Jelinek DF. Increased signaling through p62 in the marrow microenvironment increases myeloma cell growth and osteoclast formation. Blood. 2009; 113(20):4894-4902.","DOI":"10.1182\/blood-2008-08-173948"},{"key":"60750","doi-asserted-by":"crossref","unstructured":"Goodall ML, Fitzwalter BE, Zahedi S. The autophagy machinery controls cell death switching between apoptosis and necroptosis. Dev Cell. 2016; 37(4):337-349.","DOI":"10.1016\/j.devcel.2016.04.018"},{"key":"60751","doi-asserted-by":"crossref","unstructured":"Hennig P, Fenini G, Di Filippo M, Karakaya T, Beer HD. The pathways underlying the multiple roles of p62 in inflammation and cancer. Biomedicines. 2021; 9(7):707.","DOI":"10.3390\/biomedicines9070707"},{"key":"60752","doi-asserted-by":"crossref","unstructured":"Komatsu M. p62 bodies: Phase separation, NRF2 activation, and selective autophagic degradation. IUBMB Life. 2022; 74(12):1200-1208.","DOI":"10.1002\/iub.2689"},{"key":"60753","doi-asserted-by":"crossref","unstructured":"Marino S, Bishop RT, Logan JG, Mollat P, Idris AI. Pharmacological evidence for the bone-autonomous contribution of the NF\u03baB\/\u03b2-catenin axis to breast cancer related osteolysis. Cancer Lett. 2017; 410:180-190.","DOI":"10.1016\/j.canlet.2017.09.034"},{"key":"60754","doi-asserted-by":"crossref","unstructured":"Petrusca DN, Mulcrone PL, Macar DA. GFI1-dependent repression of SGPP1 increases multiple myeloma cell survival. Cancers (Basel). 2022; 14(3):772.","DOI":"10.3390\/cancers14030772"},{"key":"60755","doi-asserted-by":"crossref","unstructured":"Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010; 70(2):440-446.","DOI":"10.1158\/0008-5472.CAN-09-1947"},{"key":"60756","doi-asserted-by":"crossref","unstructured":"Shlomovitz I, Zargarian S, Erlich Z, Edry-Botzer L, Gerlic M. Distinguishing necroptosis from apoptosis. Methods Mol Biol. 2018; 1857:35-51.","DOI":"10.1007\/978-1-4939-8754-2_4"},{"key":"60757","doi-asserted-by":"crossref","unstructured":"Sabol HM, Ferrari AJ, Adhikari M. Targeting notch inhibitors to the myeloma bone marrow niche decreases tumor growth and bone destruction without gut toxicity. Cancer Res. 2021; 81(19):5102-5114.","DOI":"10.1158\/0008-5472.CAN-21-0524"},{"key":"60758","doi-asserted-by":"crossref","unstructured":"Moscat J, Diaz-Meco MT. p62 at the crossroads of autophagy, apoptosis, and cancer. Cell. 2009; 137(6):1001-1004.","DOI":"10.1016\/j.cell.2009.05.023"},{"key":"60759","unstructured":"Jourdan M, Tarte K, Legouffe E. Tumor necrosis factor is a survival and proliferation factor for human myeloma cells. Eur Cytokine Netw. 1999; 10(1):65-70."},{"key":"60760","doi-asserted-by":"crossref","unstructured":"Hayden MS, Ghosh S. Regulation of NF-\u03baB by TNF family cytokines. Semin Immunol. 2014; 26(3):253-266.","DOI":"10.1016\/j.smim.2014.05.004"},{"key":"60761","doi-asserted-by":"crossref","unstructured":"Novack DV. Role of NF-\u03baB in the skeleton. Cell Res. 2011; 21(1):169-182.","DOI":"10.1038\/cr.2010.159"},{"key":"60762","doi-asserted-by":"crossref","unstructured":"Hideshima T, Ikeda H, Chauhan D. Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood. 2009; 114(5):1046-1052.","DOI":"10.1182\/blood-2009-01-199604"},{"key":"60763","doi-asserted-by":"crossref","unstructured":"Milan E, Perini T, Resnati M. A plastic SQSTM1\/p62-dependent autophagic reserve maintains proteostasis and determines proteasome inhibitor susceptibility in multiple myeloma cells. Autophagy. 2015; 11(7):1161-1178.","DOI":"10.1080\/15548627.2015.1052928"},{"key":"60764","doi-asserted-by":"crossref","unstructured":"Zhang Y, Mun SR, Linares JF. ZZ-dependent regulation of p62\/SQSTM1 in autophagy. Nat Commun. 2018; 9(1):4373.","DOI":"10.1038\/s41467-018-06878-8"},{"key":"60765","doi-asserted-by":"crossref","unstructured":"Lopez-Corral L, Corchete LA, Sarasquete ME. Transcriptome analysis reveals molecular profiles associated with evolving steps of monoclonal gammopathies. Haematologica. 2014; 99(8):1365-1372.","DOI":"10.3324\/haematol.2013.087809"},{"key":"60766","doi-asserted-by":"crossref","unstructured":"Sha Z, Schnell HM, Ruoff K, Goldberg A. Rapid induction of p62 and GABARAPL1 upon proteasome inhibition promotes survival before autophagy activation. J Cell Biol. 2018; 217(5):1757-1776.","DOI":"10.1083\/jcb.201708168"},{"key":"60767","doi-asserted-by":"crossref","unstructured":"Cha-Molstad H, Yu JE, Feng Z. p62\/SQSTM1\/ Sequestosome-1 is an N-recognin of the N-end rule pathway which modulates autophagosome biogenesis. Nat Commun. 2017; 8(1):102.","DOI":"10.1038\/s41467-017-00085-7"},{"key":"60768","doi-asserted-by":"crossref","unstructured":"Bertheloot D, Latz E, Franklin BS. Necroptosis, pyroptosis and apoptosis: an intricate game of cell death. Cell Mol Immunol. 2021; 18(5):1106-1121.","DOI":"10.1038\/s41423-020-00630-3"},{"key":"60769","doi-asserted-by":"crossref","unstructured":"Goodall ML, Cramer SD, Thorburn A. Autophagy complexes cell death by necroptosis. Oncotarget. 2016; 7(32):50818-50819.","DOI":"10.18632\/oncotarget.10640"},{"key":"60770","doi-asserted-by":"crossref","unstructured":"Feldmann F, Schenk B, Martens S, Vandenabeele P, Fulda S. Sorafenib inhibits therapeutic induction of necroptosis in acute leukemia cells. Oncotarget. 2017; 8(40):68208-68220.","DOI":"10.18632\/oncotarget.19919"},{"key":"60771","doi-asserted-by":"crossref","unstructured":"Cho Y, McQuade T, Zhang H, Zhang J, Chan FK. RIP1-dependent and independent effects of necrostatin-1 in necrosis and T cell activation. PLoS One. 2011; 6(8):e23209.","DOI":"10.1371\/journal.pone.0023209"},{"key":"60772","doi-asserted-by":"crossref","unstructured":"Gong Y, Fan Z, Luo G. The role of necroptosis in cancer biology and therapy. Mol Cancer. 2019; 18(1):100.","DOI":"10.1186\/s12943-019-1029-8"},{"key":"60773","doi-asserted-by":"crossref","unstructured":"S\u00e1nchez-Mart\u00edn P, Saito T, Komatsu M. p62\/SQSTM1: \u2018Jack of all trades\u2019 in health and cancer. FEBS J. 2019; 286(1):8-23.","DOI":"10.1111\/febs.14712"},{"key":"60774","doi-asserted-by":"crossref","unstructured":"Najafov A, Chen H, Yuan J. Necroptosis and cancer. Trends Cancer. 2017; 3(4):294-301.","DOI":"10.1016\/j.trecan.2017.03.002"},{"key":"60775","doi-asserted-by":"crossref","unstructured":"Neumeister P, Schulz E, Pansy K, Szmyra M, Deutsch AJ. Targeting the microenvironment for treating multiple myeloma. Int J Mol Sci. 2022; 23(14):7627.","DOI":"10.3390\/ijms23147627"},{"key":"60776","doi-asserted-by":"crossref","unstructured":"Bernstein ZS, Kim EB, Raje N. Bone disease in multiple myeloma: biologic and clinical implications. Cells. 2022; 11(15):2308.","DOI":"10.3390\/cells11152308"},{"key":"60777","doi-asserted-by":"crossref","unstructured":"Wallington-Beddoe CT, Bennett MK, Vandyke K. Sphingosine kinase 2 inhibition synergises with bortezomib to target myeloma by enhancing endoplasmic reticulum stress. Oncotarget. 2017; 8(27):43602-43616.","DOI":"10.18632\/oncotarget.17115"},{"key":"60778","doi-asserted-by":"crossref","unstructured":"Xu G, Liu K, Anderson J. Expression of XBP1s in bone marrow stromal cells is critical for myeloma cell growth and osteoclast formation. Blood. 2012; 119(18):4205-4214.","DOI":"10.1182\/blood-2011-05-353300"},{"key":"60779","doi-asserted-by":"crossref","unstructured":"Ninkovic S, Harrison SJ, Quach H. Glucose-regulated protein 78 (GRP78) as a potential novel biomarker and therapeutic target in multiple myeloma. Expert Rev Hematol. 2020; 13(11):1201-1210.","DOI":"10.1080\/17474086.2020.1830372"},{"key":"60780","doi-asserted-by":"crossref","unstructured":"Ravindran S, Gao Q, Ramachandran A. Stress chaperone GRP-78 functions in mineralized matrix formation. J Biol Chem. 2011; 286(11):8729-8739.","DOI":"10.1074\/jbc.M110.179341"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.283787\/76290","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.283787\/76943","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11346\/76290","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:05:14Z","timestamp":1794045914000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.283787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,16]]},"references-count":50,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,5,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.283787","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11,16]]}}}